SciSparc (SPRC) announced initial positive pre-clinical results for treatment for obesity and the potential treatment of metabolic syndromes using MEAI, a novel psychedelic molecule of Clearmind Medicine (CMND). The results are in connection with the provisional patent application for treating metabolic syndromes including obesity with Clearmind based on SciSparc’s CannAmide’s active ingredient Palmitoylethanolamide and Clearmind’s MEAI, submitted in September 2022. "We are excited about Clearmind’s results, in light of the potential synergistic effect between SciSparc’s CannAmide and Clearmind’s MEAI, as previously demonstrated in numerous studies for several conditions with MEAI’s effective dose. According to the World Health Organization, approximately, 1 billion people worldwide, more than 30% of the global population, are overweight or obese, and we believe obesity treatment could quickly become a top-12 global therapy, growing from a $2.4 billion category in 2022 to $54 billion by 2030," commented Oz Adler, SciSparc’s Chief Executive Officer. "We believe that this virtually untapped multibillion-dollar market creates significant opportunities for our joined collaboration with Clearmind by developing a unique drug candidate for the market to treat obesity." Clearmind’s study, was conducted at the Hebrew University of Jerusalem, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI. The animals treated with MEAI showed increased energy expenditure, better fat utilization, and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed. Additionally, the treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high fat, untreated group.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SPRC:
- SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
- Jeffs’ Brands enters non-binding LOI to acquire 50% of SciSparc subsidiary
- SciSparc enters non-binding LOI to sell 50% interest in subsidiary for $3M
- SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
- SciSparc announces results of study on SCI-210 for epilepsy
